Eli Lilly (LLY) officially joined the elite group of U.S. companies valued at more than $1T on Friday, becoming the tenth American stock to currently cross the landmark threshold. The move came as ...

The Gen III TacIRST distributed infrared threat‑warning system will equip the F-22 Raptor, with an evaluation planned in 2026. Lockheed Martin has announced the first flight of the latest iteration of ...

Eli Lilly recently became the first healthcare company to surpass a $1 trillion market capitalization, propelled by surging demand for its GLP-1-based diabetes and obesity drugs, Zepbound and Mounjaro ...

In this photo illustration, a Eli Lilly logo seen displayed on a smartphone. Eli Lilly’s stock (NYSE: LLY) has recently surged 27% over the past month, reaching a current price of $1,022. This rally ...

We recently published 8 Stocks Jim Cramer Discussed & Mentioned An Important Quantum Computing Development. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer discussed. As he discussed ...

Eli Lilly and Co (NYSE: LLY) shares are trading higher on Friday. The company plans to start selling its obesity drug through a new approach aimed at expanding access. What To Know: Eli Lilly is ...

Eli Lilly is poised to become the first $1 trillion pharmaceutical company, driven by explosive growth in its weight-loss drug, Mounjaro. LLY's earnings and sales growth have been exceptional, with ...

Eli Lilly’s stock (NYSE: LLY) soared nearly 50%, in the past six months, driven not only by outstanding earnings and a notable margin increase, but also by reaching a $1T market cap and excitement ...

Eli Lilly is the market-share leader for weight-loss drugs. Coverage by government insurance programs is a huge win for the company. 10 stocks we like better than Eli Lilly › Drug giant Eli Lilly ...

Eli Lilly is the market-share leader for weight-loss drugs. Coverage by government insurance programs is a huge win for the company. One big reason Lilly stock has potential is Medicare, the ...

The stock recently reached beyond $1,000. Investors generally don't turn to pharmaceutical stocks with expectations of high growth in a short period of time. Instead, they scoop up these players for ...